Efficacy of IV Acetaminophen Versus Oral Acetaminophen

NCT ID: NCT03365622

Last Updated: 2025-06-29

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

214 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-08-08

Study Completion Date

2024-04-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to determine whether intravenous acetaminophen compared to enteric acetaminophen offers increased efficacy in patients who are scheduled for laparoscopic donor nephrectomy and for patients scheduled for robot-assisted, laparoscopic nephrectomy for cancer at the University of Rochester Medical Center. The standard surgical and post-operative care, including post-operative pain management will not be altered.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Nephrectomy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

IV acetaminophen and placebo pills

Group Type ACTIVE_COMPARATOR

acetaminophen

Intervention Type DRUG

Active Intravenous doses will consist of a single 1,000mg/100 ml IV dose with contents of commercial vials transferred to an empty sterile IV bag.

Placebo Oral Tablet

Intervention Type DRUG

Placebo, opaque capsules that have been filled with inert powder (lactose USP), 2 capsules oral every six hours for 24 hours

placebo IV (normal saline) + oral acetaminophen

Group Type PLACEBO_COMPARATOR

Acetaminophen

Intervention Type DRUG

500mg acetaminophen tablet ,2 capsules oral every six hours for 24 hours

Placebos

Intervention Type DRUG

Placebo Intravenous doses will consist of 100ml of normal saline transferred to an empty sterile IV bag.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

acetaminophen

Active Intravenous doses will consist of a single 1,000mg/100 ml IV dose with contents of commercial vials transferred to an empty sterile IV bag.

Intervention Type DRUG

Acetaminophen

500mg acetaminophen tablet ,2 capsules oral every six hours for 24 hours

Intervention Type DRUG

Placebos

Placebo Intravenous doses will consist of 100ml of normal saline transferred to an empty sterile IV bag.

Intervention Type DRUG

Placebo Oral Tablet

Placebo, opaque capsules that have been filled with inert powder (lactose USP), 2 capsules oral every six hours for 24 hours

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Be at least 18 years old
* Be scheduled for donor nephrectomy or robot-assisted, laparoscopic nephrectomy for cancer at University of Rochester Medical Center
* Have cognitive ability to verbally rate their pain on the Numeric Rating Scale (NRS).

Exclusion Criteria

* Age younger than 18 years old or older than 90 years old
* Pregnancy (Pre-operative pregnancy test is standard of care for all elective operating room cases)
* Weight less than 50 kg
* Epidural use
* History of known liver disease.
* Patient unable to take enteral medications.
* Be taking opioid medications chronically.
Minimum Eligible Age

18 Years

Maximum Eligible Age

89 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Rochester

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Joseph W Dooley, MD

Associate Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Rochester Medical Center

Rochester, New York, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Document Type: Informed Consent Form

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

70162

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Intravenous Acetaminophen in Craniotomy
NCT01598701 COMPLETED PHASE4